본문 바로가기 대메뉴 바로가기

신문방송국

HIGHHANBAT

미래가치를 창출하는 글로컬 산학일체 혁신대학

National News

Let’s get through , COVID-19

작성자HANBAT HERALD  조회수67 등록일2021-07-29
二쇱궗湲_png.png [1.5 KB]

Let’s get through , COVID-19

By Joung In-young Reporter, Sophomore of Electronics Control Engineering


Many changes in daily life have come due to COVID-19, which has been  going     

on for more than a year. Lets find out what’s happened so far and what the plan is for the future.



  1. COVID-19 vaccine in the global pharmaceutical industry.

The global pharmaceutical industry is working together to develop  technologies that can end COVID-19. The Korea International Pharmaceutical Industry Association (KRPIA) has developed a vaccine in a surprisingly short time of one year since the COVID hit the world. The KRPIA said seven vaccines have been fully approved for use worldwide. According to the COVID-19 vaccine and treatment status of the U.S. Pharmaceutical Association, a total of nine vaccines and treatments have been approved for emergency use and licensed in the U.S., 81 global vaccines and 544 global treatments are currently being tested, with a total of 1,613 clinical trials.


  1. COVID-19 vaccine development

   2-1) Pfizer and German co-developed vaccine BioNTech.

               Starting with the U.K., which announced the world's first approval for use on 

               December 2, 2020, it received emergency approval from the U.S. Food and Drug            

               Administration (FDA) on December 11. This vaccine has been shown to have 95 

               percent prevention effect in Phase III clinical trials. Pfizer and BioNTech 

               have expanded their plant for mass production of vaccines and expect to be able

               to manufacture  2 billion doses worldwide by the end of 2021.


  2-2) Modern

  Moderna was the second FDA-approved emergency used on December 18, 

              2020, following the Pfizer vaccine. Moderna launched the first clinical trial for   

              COVID-19, and developed the vaccine in collaboration with the National Institute of         

              Allergy and Infectious Diseases (NIH) with $1 billion in aid, based on the U.S.            

              government’'s vaccine development project “Super-Fast Operation.” It is expanding 

              its investment to produce 1.4 billion doses in 2022.


2-3) Ansen  

On February 27, 2021, it was the third time that a vaccine was approved for emergency use as a COVID-19 vaccine by the U.S. FDA, and it is the first vaccine to demonstrate safety and efficacy with a single dose. Johnson & Johnson (J&J) said it aims to produce 1 billion doses of the vaccine in 2021.



  2-4) AstraZeneca 

AstraZeneca is a COVID-19 vaccine developed in collaboration with the Oxford Jenner Institute in the UK. On February 10 last year, the Ministry of Food and Drug Safety gave its first permission in the UK to prevent COVID-19 caused by the SARS-CoV-2 virus in all adults aged 18 or older. It is not profitable during the COVID-19 pandemic. They are also working with various governments and major health organizations, such as the World Health Organization (WHO), to ensure rapid vaccine supplies worldwide.


  1.  Treatments and vaccines

3-1) Treatment

           Major symptoms include the administration of antibiotics to prevent antiviral 

           drugs or secondary infections. Some of the patients were found to be able to heal with     

           autoimmune without antiviral medication. In some cases, the virus lasts three to four 

weeks without symptoms. Also, even after symptoms improve, in rare cases, the virus      may reactivate, so even if the treatment is over, it is recommended to self-isolate for 

           at least two weeks.


 3-2) Characteristics of Vaccine


Manufacturer

Pfizer

Moderna

AstraZeneca

Ansen


Vaccine name


Cominati Province


Korea AstraZeneca

COVID-19 Vaccine



Platform

mRNA vaccine

(Hexane vaccine)

mRNA vaccine

(Hexane vaccine)

Virus

Vector Vaccine

Virus 

Vector Vaccine

Vaccination 

age limit

16 years of age or older

18years of age or older

18 years of age or older


Configuration

Multi-dose vial

Multi-dose vial

Multi-dose vial


Number of inoculations

(interval)


Twice, 21 days.


Twice, 28th


Twice,

 8-12 weeks


One-time

Amount and method of inoculation

Diluted vaccine

 0.3 ml muscle injection.

0.5 ml

 muscle injection

0.5 ml 

muscle injection





  1. Vaccination Plan


Vaccination

schedule

Subjects and Methods of Vaccination

4th week of March

●Hospitalization and employees aged 65 or older 

                -AstraZeneca



1st week of April

●Senior citizens aged 75 and over

    -Pfizer

●Special education workers and health teachers

    in kindergartens, elementary schools and middle schools

     -AstraZeneca

●School personal of Daycare centers and disabled

   -AstraZeneca 

2nd week of

April

●Facilities for the disabled -AstraZeneca

●Workers in correctional facilities, etc.-AstraZeneca


3rd week of

April

●Nursing Hospital for the Elderly

     -AstraZeneca

●Residential facilities for persons with tuberculosis and Hansen’'s disease

    -AstraZeneca

4th week of

April

●Homeless  residence and Utilization Facilities

    -AstraZeneca


May

●Aircrew

●Senior citizens aged 65–74 years.

-AstraZeneca





July

●Senior citizens aged 65–74 years

●Disabled Care Workers

●Senior Visiting Care Workers

●Kindergarten, daycare center, elementary school teachers

    (1st and 2nd grade), etc.

●Chronic Severe Respiratory Disease (dialysis patient)

●Workers in medical institutions and pharmacies (healthcare workers)

●Social Essentials (Police, Fire, Military, etc.)

-AstraZeneca






So far, we have looked into COVID-19 and domestic countermeasures. I would like to 

remind you once again that the number of confirmed cases is constantly decreasing. Don't let your guard down! Wearing a mask is a must!